Last reviewed · How we verify
Commercial Hepatitis B vaccine — Competitive Intelligence Brief
phase 3
Vaccine
Hepatitis B surface antigen (HBsAg)
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Commercial Hepatitis B vaccine (Commercial Hepatitis B vaccine) — Vaxine Pty Ltd. A hepatitis B vaccine that stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against HBV infection.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Commercial Hepatitis B vaccine TARGET | Commercial Hepatitis B vaccine | Vaxine Pty Ltd | phase 3 | Vaccine | Hepatitis B surface antigen (HBsAg) | |
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Quadrivalent influenza modRNA vaccine | quadrivalent-influenza-modrna-vaccine | Pfizer | marketed | Vaccine | Influenza virus | |
| FluMist trivalent (2015-2016) | FluMist trivalent (2015-2016) | MedImmune LLC | marketed | Live attenuated influenza vaccine | ||
| Pandemic influenza A/H1N1 vaccine | Pandemic influenza A/H1N1 vaccine | Sinovac Biotech Co., Ltd | marketed | inactivated influenza vaccine | ||
| Moderna mRNA-1273 COVID-19 vaccine | Moderna mRNA-1273 COVID-19 vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | marketed | mRNA vaccine | SARS-CoV-2 spike protein (S protein) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Vaccine class)
- GlaxoSmithKline · 16 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
- Pfizer · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Henogen · 3 drugs in this class
- Pfizer Inc. · 2 drugs in this class
- Sanofi · 2 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
- BioNTech · 2 drugs in this class
- Merck Sharp & Dohme LLC · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Commercial Hepatitis B vaccine CI watch — RSS
- Commercial Hepatitis B vaccine CI watch — Atom
- Commercial Hepatitis B vaccine CI watch — JSON
- Commercial Hepatitis B vaccine alone — RSS
- Whole Vaccine class — RSS
Cite this brief
Drug Landscape (2026). Commercial Hepatitis B vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/commercial-hepatitis-b-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab